PTCT Q4 2020 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$119M+23.2% YoY

Gross Profit

$114M95.9% margin

Operating Income

-$96M-81.1% margin

Net Income

-$74M-62.6% margin

EPS (Diluted)

$-1.11

QoQ Revenue Growth

+0.4%

Cash Flow

Operating Cash Flow

-$64M

Free Cash Flow

-$83M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$1.7B

Stockholders' Equity

$482M

Cash & Equivalents

$209M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$119M	$96M	+23.2%
Gross Profit	$114M	$93M	+22.7%
Operating Income	-$96M	-$73M	-32.4%
Net Income	-$74M	-$78M	+4.3%

Revenue Segments

Product

$107M90%

Grant And Collaboration

$8M6%

Royalty

$4M3%